Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues

Bibliography

• Foster CS, Vitale AT, Jakobiec FA. Diagnosis and treatment of uveitis. 2nd edition. Jaypee Brothers Medical Publishers; New Delhi; London: 2013
   Google Scholar
• Imrie FR, Dick AD. Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. Curr Opin Ophthalmol 2007;18(3):212-19
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Whitcup SM. Uveitis: fundamentals and clinical practice. 4 edition. Mosby; Edinburgh: 2010
   Google Scholar
• Bonfioli AA, Damico FM, Curi ALL, Orefice F. Intermediate uveitis. Semin Ophthalmol 2005;20(3):147-54
   PubMedGoogle Scholar
• Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect 2012;2(1):21-8
   PubMedGoogle Scholar
• Barrett JH, Brennan P, Fiddler M, Silman A. Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum 2000;43(5):1010-15
   PubMed Web of Science ®Google Scholar
• Petri M. Hopkins lupus pregnancy center: 1987 to 1996. Rheum Dis Clin North Am 1997;23(1):1-13
   PubMed Web of Science ®Google Scholar
• Khamashta MA, Ruiz-Irastorza G, Hughes GR. Systemic lupus erythematosus flares during pregnancy. Rheum Dis Clin North Am 1997;23(1):15-30
   PubMed Web of Science ®Google Scholar
• Rabiah PK, Vitale AT. Noninfectious uveitis and pregnancy. Am J Ophthalmol 2003;136(1):91-8
   PubMed Web of Science ®Google Scholar
• Bang D, Chun YS, Haam IB, et al. The influence of pregnancy on Behçet’s disease. Yonsei Med J 1997;38(6):437-43
   PubMedGoogle Scholar
• Mainini G, Di Donna MC, Esposito E, et al. Pregnancy management in Behçet’s disease treated with uninterrupted infliximab. Report of a case with fetal growth restriction and mini-review of the literature. Clin Exp Obstet Gynecol 2014;41(2):205-7
   PubMed Web of Science ®Google Scholar
• Marsal S, Falgá C, Simeon CP, et al. Behçet’s disease and pregnancy relationship study. Br J Rheumatol 1997;36(2):234-8
   PubMedGoogle Scholar
• Noel N, Wechsler B, Nizard J, et al. Behçet’s disease and pregnancy. Arthritis Rheum 2013;65(9):2450-6
   PubMed Web of Science ®Google Scholar
• Kump LI, Cervantes-Castañeda RA, Androudi SN, et al. Patterns of exacerbations of chronic non-infectious uveitis in pregnancy and puerperium. Ocul Immunol Inflamm 2006;14(2):99-104
   PubMed Web of Science ®Google Scholar
• Chiam NPY, Hall AJH, Stawell RJ, et al. The course of uveitis in pregnancy and postpartum. Br J Ophthalmol 2013;97(10):1284-8
   PubMed Web of Science ®Google Scholar
• Agarwal RK, Chan CC, Wiggert B, Caspi RR. Pregnancy ameliorates induction and expression of experimental autoimmune uveitis. J Immunol 1999;162(5):2648-54
   PubMed Web of Science ®Google Scholar
• Chan C-C, Reed GF, Kim Y, et al. A correlation of pregnancy term, disease activity, serum female hormones, and cytokines in uveitis. Br J Ophthalmol 2004;88(12):1506-9
   PubMed Web of Science ®Google Scholar
• Oka M. Activity of rheumatoid arthritis and plasma 17-hydroxycorticosteroids during pregnancy and following parturition: report on two cases. Acta Rheumatol Scand 1958;4(4):243-8
   PubMedGoogle Scholar
• Progesterone in large amounts has immunosuppressive effect. JAMA 1976;236(4):905-13
   PubMedGoogle Scholar
• Lipton JM. Modulation of host defense by the neuropeptide alpha-MSH. Yale J Biol Med 1990;63(2):173-82
   PubMed Web of Science ®Google Scholar
• Lipton JM, Catania A. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol Today 1997;18(3):140-5
   PubMedGoogle Scholar
• Whyte A, Williams RO. Bromocriptine suppresses postpartum exacerbation of collagen-induced arthritis. Arthritis Rheum 1988;31(7):927-8
   PubMed Web of Science ®Google Scholar
• Musiej-Nowakowska E, Ploski R. Pregnancy and early onset pauciarticular juvenile chronic arthritis. Ann Rheum Dis 1999;58(8):475-80
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Mandal C. Immuno-suppressive effect of human alphafetoprotein: a cross species study. Immunol Invest 1993;22(5):329-39
   PubMed Web of Science ®Google Scholar
• Matsuura E, Kang Y, Kitakawa H, et al. Modulation of T cell function by alpha-fetoprotein: An in vivo study on porcine thyroid peroxidase-induced experimental autoimmune thyroiditis in transgenic mice producing human alpha-fetoprotein. Tumour Biol 1999;20(3):162-71
   PubMed Web of Science ®Google Scholar
• Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993;14(7):353-6
   PubMedGoogle Scholar
• Elenkov IJ, Wilder RL, Bakalov VK, et al. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab 2001;86(10):4933-8
   PubMed Web of Science ®Google Scholar
• Ernerudh J, Berg G, Mjösberg J. Regulatory T helper cells in pregnancy and their roles in systemic versus local immune tolerance. Am J Reprod Immunol 2011;66(Suppl 1):31-43
   PubMedGoogle Scholar
• Williams Z. Inducing tolerance to pregnancy. N Engl J Med 2012;367(12):1159-61
   PubMed Web of Science ®Google Scholar
• Takayama K, Ishikawa S, Enoki T, et al. Successful treatment with infliximab for Behçet disease during pregnancy. Ocul Immunol Inflamm 2013;21(4):321-3
   PubMed Web of Science ®Google Scholar
• Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72(Suppl 2):ii2-34
   PubMed Web of Science ®Google Scholar
• Yarur A, Kane SV. Update on pregnancy and breastfeeding in the era of biologics. Dig Liver Dis 2013;45(10):787-94
   PubMedGoogle Scholar
• Wakefield D, Abu El-Asrar A, McCluskey P. Treatment of severe inflammatory eye disease in patients of reproductive age and during pregnancy. Ocul Immunol Inflamm 2012;20(4):277-87
   PubMed Web of Science ®Google Scholar
• Sammaritano LR, Bermas BL. Rheumatoid arthritis medications and lactation. Curr Opin Rheumatol 2014;26(3):354-60
   PubMed Web of Science ®Google Scholar
• Gerosa M, Meroni PL, Cimaz R. Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opin Drug Saf 2014;13(12):1591-9
   PubMed Web of Science ®Google Scholar
• Gotovac M, Kastelan S, Lukenda A. Eye and pregnancy. Coll Antropol 2013;37(Suppl 1):189-93
   PubMedGoogle Scholar
• Johnson SM, Martinez M, Freedman S. Management of glaucoma in pregnancy and lactation. Surv Ophthalmol 2001;45(5):449-54
   PubMed Web of Science ®Google Scholar
• Méndez-Hernández C. Use of glaucoma medications during pregnancy and breastfeeding. Arch Soc Esp Oftalmol 2012;87(12):389-91
   PubMedGoogle Scholar
• Tien MCH, Teoh SCB. Treatment of Vogt-Koyanagi-Harada syndrome in pregnancy. Can J Ophthalmol 2009;44(2):211-12
   PubMed Web of Science ®Google Scholar
• Doi M, Matsubara H, Uji Y. Vogt-Koyanagi-Harada syndrome in a pregnant patient treated with high-dose systemic corticosteroids. Acta Ophthalmol Scand 2000;78(1):93-6
   PubMedGoogle Scholar
• Miyata N, Sugita M, Nakamura S, et al. Treatment of Vogt-Koyanagi- Harada’s disease during pregnancy. Jpn J Ophthalmol 2001;45(2):177-80
   PubMed Web of Science ®Google Scholar
• Jap A, Chee S-P. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol 2008;19(6):535-40
   PubMed Web of Science ®Google Scholar
• Keeling SO, Oswald AE. Pregnancy and rheumatic disease: «by the book» or «by the doc». Clin Rheumatol 2009;28(1):1-9
   PubMed Web of Science ®Google Scholar
• Martínez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 2009;27(4):678-84
   PubMed Web of Science ®Google Scholar
• Schatz M, Patterson R, Zeitz S, et al. Corticosteroid therapy for the pregnant asthmatic patient. JAMA 1975;233(7):804-7
   PubMed Web of Science ®Google Scholar
• Steahly LP. Vogt-Koyanagi-Harada syndrome and pregnancy. Ann Ophthalmol 1990;22(2):59-62
   PubMed Web of Science ®Google Scholar
• Sawady J, Mercer BM, Wapner RJ, et al. The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Beneficial Effects of Antenatal Repeated Steroids study: impact of repeated doses of antenatal corticosteroids on placental growth and histologic findings. Am J Obstet Gynecol 2007;197(3):281.e1-8
   PubMedGoogle Scholar
• Moore KL, Persaud TVN. The developing human: clinically oriented embryology. 5th edition. Saunders; Philadelphia: 1993
   Google Scholar
• Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann NY Acad Sci 2014;1317:32-8
   PubMed Web of Science ®Google Scholar
• Jain A, Venkataramanan R, Fung JJ, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997;64(4):559-65
   PubMed Web of Science ®Google Scholar
• Grimer M; Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Calcineurin inhibitors in renal transplantation: pregnancy, lactation and calcineurin inhibitors. Nephrology (Carlton) 2007;12(Suppl 1):S98-105
   PubMedGoogle Scholar
• Kainz A, Harabacz I, Cowlrick IS, et al. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int 2000;13(Suppl 1):S299-300
   PubMedGoogle Scholar
• Armenti VT, Moritz MJ, Davison JM. Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes. Drug Saf 1998;19(3):219-32
   PubMed Web of Science ®Google Scholar
• Verstappen SMM, King Y, Watson KD, et al. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70(5):823-6
   PubMed Web of Science ®Google Scholar
• Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol 2011;32(1):93-7
   PubMed Web of Science ®Google Scholar
• Stengel J-Z, Arnold H-L. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008;14(19):3085-7
   PubMed Web of Science ®Google Scholar
• Klink DT, van Elburg RM, Schreurs MWJ, van Well GTJ. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008;2008:271363
   PubMedGoogle Scholar
• Vinet E, Pineau C, Gordon C, et al. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 2009;61(5):587-92
   PubMed Web of Science ®Google Scholar
• Østensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology 2008;47(Suppl 3):iii28-31
   PubMedGoogle Scholar
• Lloyd ME, Carr M, McElhatton P, et al. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999;92(10):551-63
   PubMed Web of Science ®Google Scholar
• Kim M, Rostas S, Gabardi S. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. Am J Transplant 2013;13(6):1383-9
   PubMed Web of Science ®Google Scholar
• Motta M, Tincani A, Lojacono A, et al. Neonatal outcome in patients with rheumatic disease. Lupus 2004;13(9):718-23
   PubMed Web of Science ®Google Scholar
• Matalon ST, Ornoy A, Lishner M. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol 2004;18(2):219-30
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol 2014;43:78-84
   PubMed Web of Science ®Google Scholar
• Onal S, Foster CS, Ahmed AR. Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocul Immunol Inflamm 2006;14(6):367-74
   PubMed Web of Science ®Google Scholar
• Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 2008;146(6):802-12
   PubMed Web of Science ®Google Scholar
• Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 2007;7(2):96-101
   PubMed Web of Science ®Google Scholar
• Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003;76(6):984-8
   PubMed Web of Science ®Google Scholar
• Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study. Arthritis Rheum 1995;38(8):1120-7
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116(6):488-98
   PubMed Web of Science ®Google Scholar
• Puri HC, Campbell RA. Cyclophosphamide and malignancy. Lancet 1977;1(8025):1306
   PubMed Web of Science ®Google Scholar
• Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005;80(9):1233-43
   PubMed Web of Science ®Google Scholar
• Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4(2):222-30
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001;71(8):1065-8
   PubMed Web of Science ®Google Scholar
• Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000;70(1):94-9
   PubMed Web of Science ®Google Scholar
• Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 2002;8(10):939-44
   PubMed Web of Science ®Google Scholar
• Yakupoglu YK, Buell JF, Woodle S, Kahan BD. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc 2006;38(2):358-61
   PubMed Web of Science ®Google Scholar
• Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004;18(4):446-9
   PubMed Web of Science ®Google Scholar
• Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002;16(7):1225-32
   PubMed Web of Science ®Google Scholar
• Hazleman BL. The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. Ann Rheum Dis 1982;41(Suppl 1):12-17
   PubMed Web of Science ®Google Scholar
• Jensen P, Møller B, Hansen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 2000;42(2 Pt 1):307
   PubMed Web of Science ®Google Scholar
• Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997;26(6):794-804
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56(5):1433-9
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(9):2757-64
   PubMed Web of Science ®Google Scholar
• Jacobsson LTH, Turesson C, Nilsson J-A, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66(5):670-5
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64(10):1421-6
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64(10):1414-20
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56(9):2886-95
   PubMed Web of Science ®Google Scholar
• Lindelöf B, Sigurgeirsson B, Gäbel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000;143(3):513-19
   PubMed Web of Science ®Google Scholar
• Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990;49(3):506-9
   PubMed Web of Science ®Google Scholar
• Blohmé I, Larkö O. Skin lesions in renal transplant patients after 10-23 years of immunosuppressive therapy. Acta Derm Venereol 1990;70(6):491-4
   PubMed Web of Science ®Google Scholar
• Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi’s sarcoma. J Natl Cancer Inst 2002;94(22):1712-18
   PubMed Web of Science ®Google Scholar
• Guo WX, Antakly T. AIDS-related Kaposi’s sarcoma: evidence for direct stimulatory effect of glucocorticoid on cell proliferation. Am J Pathol 1995;146(3):727-34
   PubMed Web of Science ®Google Scholar
• Mezalek ZT, Harmouche H, Attar NE, et al. Kaposi’s sarcoma in association with Behcet’s disease: case report and literature review. Semin Arthritis Rheum 2007;36(5):328-31
   PubMed Web of Science ®Google Scholar
• Kötter I, Aepinus C, Graepler F, et al. HHV8 associated Kaposi’s sarcoma during triple immunosuppressive treatment with cyclosporine A, azathioprine, and prednisolone for ocular Behçet’s disease and complete remission of both disorders with interferon alpha. Ann Rheum Dis 2001;60(1):83-6
   PubMed Web of Science ®Google Scholar
• Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999;12(2):200-17
   PubMed Web of Science ®Google Scholar
• Biemer JJ. Malignant lymphomas associated with immunodeficiency states. Ann Clin Lab Sci 1990;20(3):175-91
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. 4th edition. World Health Organization; Lyon, France: 2008
   Google Scholar
• Kingsmore SF, Hall BD, Allen NB, et al. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 1992;19(9):1462-5
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Liang L-C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44(2):265-7
   PubMed Web of Science ®Google Scholar
• Kamel OW. Iatrogenic lymphoproliferative disorders in nontransplantation settings. Semin Diagn Pathol 1997;14(1):27-34
   PubMed Web of Science ®Google Scholar
• Koch DG, Christiansen L, Lazarchick J, et al. Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl 2007;13(6):904-12
   PubMed Web of Science ®Google Scholar
• Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14(6):1943-9
   PubMed Web of Science ®Google Scholar
• Zhan X, Brown B, Slobod KS, Hurwitz JL. Inhibition of ex vivo-expanded cytotoxic T-lymphocyte function by high-dose cyclosporine. Transplantation 2003;76(4):739-40
   PubMed Web of Science ®Google Scholar
• Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328(18):1317-21
   PubMed Web of Science ®Google Scholar
• Adams B, Lazarchick J, Medina AM, et al. Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol 2010;85(8):627-9
   PubMed Web of Science ®Google Scholar
• Hunt SA. Malignancy in organ transplantation: heart. Transplant Proc 2002;34(5):1874-6
   PubMed Web of Science ®Google Scholar
• Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993;55(4):742-7
   PubMed Web of Science ®Google Scholar
• Pham T, Bachelez H, Berthelot J-M, et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78(Suppl 1):15-185
   PubMed Web of Science ®Google Scholar
• Tarantola RM, Folk JC, Boldt HC, Mahajan VB. Intravitreal bevacizumab during pregnancy. Retina 2010;30(9):1405-11
   PubMed Web of Science ®Google Scholar
• Elliott AB, Chakravarty EF. Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Womens Health (Lond Engl) 2010;6(3):431-40
   PubMedGoogle Scholar